Cancer Cell

Article	Citations
Oxidative Stress in Cancer	1339
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy	569
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker	538
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth	533
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities	461
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion	416
Engineering CAR-T Cells for Next-Generation Cancer Therapy	371
Proteogenomic and metabolomic characterization of human glioblastoma	344
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes	327
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer	318
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments	316
CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4	310
Clinical Challenges of Immune Checkpoint Inhibitors	301
Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer	298
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma	295
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade	292
Challenges and Opportunities for Pancreatic Cancer Immunotherapy	292
MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate	285
Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation	284
Seroconversion rates following COVID-19 vaccination among patients with cancer	274
Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma	272
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma	250
Microbiome and cancer	241
Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells	240
Targeting cell-cycle machinery in cancer	236

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial	229
Emergence of a High-Plasticity Cell State during Lung Cancer Evolution	222
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies	221
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors	216
YTHDF3 Induces the Translation of m6A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis	215
Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver	210
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial	209
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma	206
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma	203
Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma	202
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy	201
Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer	198
Immunometabolic Interplay in the Tumor Microenvironment	195
COVID-19 and Cancer: Current Challenges and Perspectives	194
SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19	188
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer	187
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer	184
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade	181
Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states	180
Mutant p53 suppresses innate immune signaling to promote tumorigenesis	177
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer	177
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification	176
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity	176
Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer	173
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma	173
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations	166
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL	166
Biomolecular Condensates and Cancer	166
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity	164
Immune phenotypic linkage between colorectal cancer and liver metastasis	159
Artificial intelligence for clinical oncology	154
Artificial intelligence for multimodal data integration in oncology	154
Single-Cell Characterization of Malignant Phenotypes and Developmental Trajectories of Adrenal Neuroblastoma	151
Integrated Omics of Metastatic Colorectal Cancer	151
An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence	151
Single-Cell Multiomics Sequencing Reveals Prevalent Genomic Alterations in Tumor Stromal Cells of Human Colorectal Cancer	149
Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma	149
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer	146
Immunomodulation by targeted anticancer agents	146
IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis	146
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer	145
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial	144
Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma	143
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site	140
Pan-cancer integrative histology-genomic analysis via multimodal deep learning	140
Tumor organoids: Opportunities and challenges to guide precision medicine	139
Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy	137
The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer	136
Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer	135
The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth	135

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma	134
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity	134
Activating a collaborative innate-adaptive immune response to control metastasis	132
Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer	130
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer	128
Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription	125
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms	125
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma	124
Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence	124
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations	123
SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways	120
MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway	119
N6-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation	118
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress	116
Metabolic programming and immune suppression in the tumor microenvironment	114
Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment	114
High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer	111
Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance	110
The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1	110
Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy	110
Melanoma models for the next generation of therapies	109
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia	109
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage	107
Immunogenomic Landscape of Hematological Malignancies	107
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies	105
Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer	104
Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance	103
Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity	103
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer	102
Integrin αvβ6–TGFβ–SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer	102
Evaluation of cell-free DNA approaches for multi-cancer early detection	102
Targeting pan-essential genes in cancer: Challenges and opportunities	102
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy	101
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion	101
Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer	99
Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis	98
Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma	98
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study	97
Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas	96
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells	94
Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity	93
Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies	93
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance	89
Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients	89
The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia	88
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma	86
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer	85
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor	84
Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance	84
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia	83
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy	82
PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression	82
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity	81
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer	81
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers	80
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation	79
A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer	79
The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support	78
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance	78
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies	78
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies	75
Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity	74
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies	74
Pan-cancer proteomic map of 949 human cell lines	73
Selective Inhibition of STRN3-Containing PP2A Phosphatase Restores Hippo Tumor-Suppressor Activity in Gastric Cancer	72
Epigenomic Reprogramming as a Driver of Malignant Glioma	72
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients	71
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis	71
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective	71
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment	70
Tumor heterogeneity	70
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin	70
From bench to bedside: Single-cell analysis for cancer immunotherapy	70
Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function	69
Cytokine Storms in Cancer and COVID-19	69
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer	69
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance	68
IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer	68
Activated fibroblasts in cancer: Perspectives and challenges	67
Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia	67

Innate immune cells in the tumor microenvironment	67
Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells	66
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity	66
Cell Lineage-Based Stratification for Glioblastoma	66
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer	65
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers	65
Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis	64
Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity	63
Molecular classification and diagnostics of upper urinary tract urothelial carcinoma	63
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia	63
Spatial profiling technologies illuminate the tumor microenvironment	62
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma	60
The proteogenomic subtypes of acute myeloid leukemia	60
TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma	59
Tumor microbiome links cellular programs and immunity in pancreatic cancer	59
B cells and cancer	59
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness	58
The therapeutic window of antibody drug conjugates: A dogma in need of revision	58
Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells	58
H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model	58
Transcriptome analysis reveals tumor microenvironment changes in glioblastoma	57
Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes	56
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy	56
Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer	55
Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients	55
Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer	55
COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer	54
Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy	53
Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation	53
STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma	53
Interleukin-1 in tumor progression, therapy, and prevention	52
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors	52
Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy	52
STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma	52
Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop	52
Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future	52
Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study	51
Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma	51
Functional Genomics for Cancer Drug Target Discovery	50
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity	49
A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy	49
MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer	49
FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer	48
NETworking with cancer: The bidirectional interplay between cancer and neutrophil extracellular traps	48
The translational challenges of precision oncology	48
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity	48
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma	48